| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | MED24; SURF5; surf-5 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human MED22 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于MED22抗体的3篇参考文献示例(注：以下内容为示例性质，具体文献请通过学术数据库核实)：
1. **文献名称**: "Mediator subunit MED22 regulates Ras signaling to control genome integrity and tumorigenesis"
**作者**: Poss ZC, et al.
**摘要**: 该研究揭示了MED22通过调节Ras信号通路维持基因组稳定性，其缺失导致DNA损伤积累并促进肿瘤发生。作者使用特异性抗体证实MED22与Ras效应蛋白的相互作用。
2. **文献名称**: "Structure and functional analysis of the Mediator middle module"
**作者**: Tsai KL, et al.
**摘要**: 通过冷冻电镜解析中介体复合物中模块结构，发现MED22在连接Mediator头部和尾部中的关键构象变化作用，抗体阻断实验表明其影响RNA聚合酶II的招募。
3. **文献名称**: "Dysregulation of Mediator complex subunit MED22 accelerates AML progression"
**作者**: Wang Y, et al.
**摘要**: 研究发现MED22在急性髓系白血病(AML)中表达下调，通过ChIP-seq(使用MED22抗体)证实其调控造血分化相关基因，缺失导致白血病干细胞自我更新增强。
建议通过PubMed或Web of Science检索最新文献，使用关键词“MED22 antibody”或“Mediator complex subunit 22”获取准确信息。
MED22. a subunit of the Mediator complex, plays a critical role in regulating RNA polymerase II (Pol II)-dependent transcription. The Mediator complex acts as a molecular bridge between transcription factors and the basal transcriptional machinery, facilitating the initiation and elongation phases of gene expression. MED22 (also known as MED17 in some contexts) is evolutionarily conserved and contributes to the structural integrity of the Mediator’s middle module, which is essential for stabilizing interactions between Mediator, Pol II, and regulatory proteins. Studies have shown that MED22 is involved in diverse cellular processes, including cell cycle progression, differentiation, and stress responses. Dysregulation of MED22 has been linked to diseases such as cancer, where altered Mediator activity can drive oncogenic transcription programs.
Antibodies targeting MED22 are vital tools for investigating its function and interactions. These antibodies are typically developed using immunogenic peptides or recombinant protein fragments, validated for specificity via techniques like Western blotting, immunofluorescence, or chromatin immunoprecipitation (ChIP). They enable researchers to map MED22’s localization, protein-protein interactions, and its role in gene-specific regulatory mechanisms. Recent applications include studying Mediator complex dynamics in single-cell assays or CRISPR-based screens. However, challenges remain in distinguishing MED22 from homologous subunits or splice variants, emphasizing the need for rigorous validation. Overall, MED22 antibodies are indispensable for unraveling transcriptional regulation and its pathological disruptions.
×
